Maintenance therapy in AML: The past, the present and the future.
Antineoplastic Agents
/ therapeutic use
Clinical Trials as Topic
Combined Modality Therapy
DNA Methylation
/ drug effects
Disease-Free Survival
Drug Resistance, Neoplasm
Hematopoietic Stem Cell Transplantation
Humans
Immunotherapy
Interferons
/ therapeutic use
Interleukin-2
/ therapeutic use
Leukemia, Myeloid, Acute
/ mortality
Maintenance Chemotherapy
Molecular Targeted Therapy
Multicenter Studies as Topic
Neoplasm Proteins
/ antagonists & inhibitors
Neoplasm, Residual
Recurrence
Remission Induction
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
12
06
2019
revised:
13
08
2019
accepted:
15
08
2019
pubmed:
21
8
2019
medline:
27
3
2020
entrez:
21
8
2019
Statut:
ppublish
Résumé
Curative treatment in acute myeloid leukemia (AML) depends on successful induction therapy to achieve a complete remission (CR), and subsequent post-remission therapy to prevent relapse. High relapse rates after consolidation therapy and after allogeneic stem cell transplant contribute to suboptimal outcomes in AML patients, and continue to represent a difficult challenge. Effective maintenance therapy could play an important role in prolonging the remission interval in the post-consolidation setting, especially in high risk AML patients. Maintenance treatment approaches based on conventional chemotherapy, immunotherapy, hypomethylating agents, and targeted small molecules have been explored in this setting, but no data so far have been convincing enough to establish this approach as the standard of care. However, ongoing and future studies including novel targeted therapies may demonstrate promising efficacy that could facilitate incorporation of maintenance therapy into clinical practice. In this review we summarize previous and ongoing approaches of maintenance therapy in AML and discuss the most promising strategies.
Substances chimiques
Antineoplastic Agents
0
Interleukin-2
0
Neoplasm Proteins
0
Interferons
9008-11-1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1254-1265Subventions
Organisme : This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors
Pays : International
Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Almeida AM, Ramos F. Acute myeloid leukemia in the older adults. Leuk Res Rep. 2016;6:1-7.
Rashidi A, Weisdorf DJ, Bejanyan N, et al. Treatment of relapsed/refractory acute myeloid leukaemia in adults. Br J Haematol. 2018;181(1):27-37.
Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and leukemia group B. N Engl J Med. 1994;331(14):896-903.
Medeiros BC, Othus M, Appelbaum FR. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364(22):2166-2169.
Hengeveld M, Suciu S, Karrasch M, et al. Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. Ann Hematol. 2012;91(6):825-835.
Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577.
Dührsen U, Broszeit-Luft S, Dieing A, et al. Rituximab maintenance therapy of follicular lymphoma in clinical practice. Cancer Med. 2018;7:2903-2912.
Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111-121.
Liang B, Zheng Z, Shi Y, et al. Maintenance therapy with all-trans retinoic acid and arsenic trioxide improves relapse-free survival in adults with low- to intermediate-risk acute promyelocytic leukemia who have achieved complete remission after consolidation therapy. Onco Targets Ther. 2017;10:2305-2313.
Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995;332:217.
Schlenk RF. Post-remission therapy for acute myeloid leukemia. Haematologica. 2014;99(11):1663-1670.
Ivey A, Hills RK, Simpson MA, et al. Assessment of minimal residual disease in Standard-Risk AML. N Engl J Med. 2016;374:422-433.
Hirsch P, Tang R, Abermil N, et al. Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia. Haematologica. 2017;102(7):1227-1237.
Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447.
Ellison RR, Holland JF, Weil M, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood. 1968;32(4):507-523.
Cassileth PA, Harrington DP, Hines JD, et al. Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol. 1988;6(4):583-587.
Preisler H, Davis RB, Kirshner J, et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. Blood. 1987;69(5):1441-1449.
Lowenberg B, Suciu S, Archimbaud E, et al. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. Mitoxantrone versus daunorubicin in inductionconsolidation chemotherapy-the value of lowdose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. J Clin Oncol. 1998;16(3):872-881.
Ferrero D, Crisà E, Marmont F, et al. Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents. Ann Hematol. 2014;93(8):1391-1400.
Choi YW, Jeong SH, Ahn MS, et al. Oral maintenance chemotherapy with 6-mercaptopurine and methotrexate in patients with acute myeloid leukemia ineligible for transplantation. J Korean Med Sci. 2015;30(10):1416-1422.
Büchner T, Urbanitz D, Hiddemann W, et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol. 1985;3(12):1583-1589.
Burnett A, Russell N, Freeman S, et al. A comparison of limited consolidation chemotherapy therapy or not, and demethylation maintenance or not in older patients with AML and high risk MDS: Long term results of the UKNCRI AML16 trial. Haematologica. 2015;(S1):100-513.
Huls G, Chitu DA, Havelange V, et al. Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. Blood. 2019;133(13):1457-1464.
Roboz GJ, Montesinos P, Selleslag D, et al. Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. Future Oncol. 2016;12(3):293-302.
Blum W, Sanford BL, Klisovic R, et al. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 cancer and leukemia group B study (CALGB 10503). Leukemia. 2017;31(1):34-39.
Boumber Y, Kantarjian H, Jorgensen J, et al. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia. 2012;26(11):2428-2431.
Oshikawa G, Kakihana K, Saito M, et al. Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia. Br J Haematol. 2015;169(5):756-759.
Pusic I, Choi J, Fiala MA, et al. Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2015;21(10):1761-1769.
Wei A, Lewis ID, Hahn U, et al. Maintenance lenalidomide for adults aged 18−65 years with AML in first complete remission after intensive chemotherapy: a phase IB dose-escalation study of the Australasian leukemia and lymphoma group (allg). Blood. 2014;124:944.
Hunault-Berger M, Maillard N, Himberlin C, et al. Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial. Blood Cancer J. 2017;7(6):e568.
Anguille S, Lion E, Willemen Y, van Tendeloo VFI, Berneman ZN, Smits ELJM. Interferon-α in acute myeloid leukemia: an old drug revisited. Leukemia. 2011;25(5):739-748.
Smits EJM, Anguille S, Berneman ZN. Interferon α may be back on track to treat acute myeloid leukemia. Oncoimmunology. 2013;2(4):e23619.
Palva IP, Almqvist A, Elonen E, et al. Value of maintenance therapy with chemotherapy or interferon during remission of acute myeloid leukaemia. Eur J Haematol. 1991;47(3):229-233.
Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Medical Research Council Adult Leukemia Working Party. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1302-1311.
Lehmann C, Zeis M, Uharek L. Activation of natural killer cells with interleukin 2 (IL-2) and IL-12 increases perforin binding and subsequent lysis of tumour cells. Br J Haematol. 2001;114(3):660-665.
Wang KS, Frank DA, Ritz J. Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood. 2000;95(10):3183-3190.
Meloni G, Vignetti M, Pogliani E, et al. Interleukin-2 therapy in relapsed acute myelogenous leukemia. Cancer J Sci Am. 1997;3(suppl 1):S43-S47.
Petit A, Ducassou S, Leblanc T, et al. Relevance of a 1-year maintenance therapy with interleukin-2 in the treatment of childhood acute myeloid leukemia: results from the French multicenter, phase III, randomized controlled SFCE trial, ELAM02. Blood. 2014;124(21):378.
Brune M, Castaigne S, Catalano J, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood. 2006;108(1):88-96.
Austin R, Smytha MJ, Lanea SW. Harnessing the immune system in acute myeloid leukaemia. Crit Rev Oncol Hematol. 2016;103:62-77.
Molldrem J, Dermime S, Parker K, et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood. 1996;88(7):2450-2457.
Qazilbash MH, Wieder E, Thall PF, et al. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia. 2017;31(3):697-704.
Wang X, Urak R, Walter M, et al. Lenalidomide enhances the function of CS1 chimeric antigen receptor redirected-T cells against multiple myeloma. Blood. 2016;128:812.
Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2:36.
Reddy N, Hernandez-Ilizaliturri F, Roth M, et al. Lenalidomide enhances rituximab anti-tumor activity by inducing expansion, activation and tumor infiltration of Natural killer (NK) cells, as well as alters the tumor microenvironment and inhibits angiogenesis. AACR Annual Meeting; 2007, Abstract 3545.
Pollyea DA, Kohrt HE, Gallegos L, et al. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia. 2012;26:893-901.
Ramsingh G, Westervelt P, Cashen AF, et al. A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML. Leukemia. 2013;27:725-728.
Pollyea DA, Zehnder J, Coutre S, et al. Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica. 2013;98:591-596.
Löwenberg B, Beck J, Graux C, et al. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood. 2010;115(13):2586-2591.
Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121:4854-4860.
Kadia TM, Cortes J, Ghorab A, et al. Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients. J Clin Oncol. 2018;36(15):7014.
Röllig C, Serve H, Hüttmann A, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16(16):1691-1699.
Serve H, Krug U, Wagner R, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol. 2013;31(25):3110-3118.
Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454-464.
Perl A, Martinelli G, Cortes J, et al. Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial. Cancer Research. 2019;3:392-393. https://doi.org/10.1097/01.HS9.0000561784.84381.11
Stein EM, DiNardo C, Pollyea D, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130:722-732.
DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1 - mutated relapsed or refractory AML. N Engl J Med. 2018;378:2386-2398.
tein EM, DiNardo CD, Fathi AT, et al. Ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation is safe, effective, and leads to MRD-negative complete remissions. 2018 560.
Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10:375-388.
Lagadinou ED, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12:329-341.
DiNardo C, Pratz P, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7-17.
Pinto A, Maio M, Attadia V, et al. Modulation of HLA-DR antigen expression in human myeloid leukemic cells by cytarabine and 5-aza-2′-deoxycytidine. Lancet. 1984;2:867-868.
Coral S, Sigalotti L, Gasparollo A, et al. Prolonged upregulation of the expression of HLA class I antigen and costimulatory molecules on melanoma cells treated with 5-a2′-deoxycytidine. J Immunother. 1999;22:16-24.
Goodyear OC, Dennis M, Jilani NY, et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012;119(14):3361-3369.
Kröger N, Stübig T, Atanackovic D. Immune-modulating drugs and hypomethylating agents to prevent or treat relapse after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(2):168-172.
Jabbour E, Giralt S, Kantarjian H, et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer. 2009;115(9):1899-1905.
Maples KT, Sabo RT, McCarty JM, et al. Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies. Leuk Lymphoma. 2018;59(12):2836-2841.
de Lima M, Oran B, Champlin RE, et al. cc-486 maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes. Biol Blood Marrow Transplant. 2018;000:1-8.
Komrokji AP, List AF. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes. Ann Oncol. 2016;27(1):62-68.
Ades L, Prebet T, Stamatoullas A, et al. Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies. Haematologica. 2017;102(4):728-735.
Sebaa A, Ades L, Baran-Marzack F, et al. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. Genes Chromosomes Cancer. 2012;51(12):1086-1092.
Sockel K, Bornhaeuser M, Mischak-Weissinger E, et al. Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial. Haematologica. 2012;97(9):e34-e35.
Kneppers E, van der Holt B, Kersten MJ, et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 trial. Blood. 2011;118:2413-2419.
Small D. FLT3 mutations: biology and treatment. Hematology Am Soc Hematol Educ Program. 2006;2006:178-184.
DeZern AE, Sung A, Kim S, et al. Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly-diagnosed patients from a single institution. Blood Marrow Transplant. 2011;17(9):1404-1409.
Ho AD, Schetelig J, Bochtler T, et al. Allogeneic stem cell transplantation improves survival in patients with acute myeloid leukemia characterized by a high allelic ratio of mutant flt3-itd. Biol Blood Marrow Transplant. 2016;22(3):462-469.
Burchert B, Bug G, Finke J, et al. Sorafenib as maintenance therapy post allogeneic stem cell transplantation for FLT3-ITD positive AML: results from the randomized, double-blind, placebo-controlled multicentre sormain trial. Blood. 2018;132:661.
Sandmaier BM, Khaled S, Oran B, Gammon G, Trone D, Frankfurt O. Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant. Am J Hematol. 2018;93(2):222-231.